JAMP GUANFACINE XR DIN 02523582
Status: Marketed
Holder: JAMP PHARMA CORPORATION
Molecule: GUANFACINE (GUANFACINE HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C02AC02 GUANFACINE |
| Original market date | 27-Jan-2022 |
| Current status date | 27-Jan-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GUANFACINE (GUANFACINE HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02525151 | AG-GUANFACINE XR | ANGITA PHARMA INC. | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG | Marketed |
| 02525143 | AG-GUANFACINE XR | ANGITA PHARMA INC. | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG | Marketed |
| 02525135 | AG-GUANFACINE XR | ANGITA PHARMA INC. | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG | Marketed |
| 02525127 | AG-GUANFACINE XR | ANGITA PHARMA INC. | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG | Marketed |
| 02523728 | APO-GUANFACINE XR | APOTEX INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG | Marketed |
| 02523744 | APO-GUANFACINE XR | APOTEX INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG | Marketed |
| 02523752 | APO-GUANFACINE XR | APOTEX INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG | Marketed |
| 02523736 | APO-GUANFACINE XR | APOTEX INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG | Marketed |
| 02409100 | INTUNIV XR | TAKEDA CANADA INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG | Marketed |
| 02409119 | INTUNIV XR | TAKEDA CANADA INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG | Marketed |
| 02409127 | INTUNIV XR | TAKEDA CANADA INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG | Marketed |
| 02409135 | INTUNIV XR | TAKEDA CANADA INC | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG | Marketed |
| 02523574 | JAMP GUANFACINE XR | JAMP PHARMA CORPORATION | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG | Marketed |
| 02523566 | JAMP GUANFACINE XR | JAMP PHARMA CORPORATION | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG | Marketed |
| 02523558 | JAMP GUANFACINE XR | JAMP PHARMA CORPORATION | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG | Marketed |
| 02525224 | PRO-GUANFACINE XR | PRO DOC LIMITEE | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG | Marketed |
| 02525232 | PRO-GUANFACINE XR | PRO DOC LIMITEE | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG | Marketed |
| 02525240 | PRO-GUANFACINE XR | PRO DOC LIMITEE | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG | Marketed |
| 02525259 | PRO-GUANFACINE XR | PRO DOC LIMITEE | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG | Marketed |
| 02563185 | SANDOZ GUANFACINE XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG | Marketed |
| 02563193 | SANDOZ GUANFACINE XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG | Marketed |
| 02563207 | SANDOZ GUANFACINE XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG | Marketed |
| 02563215 | SANDOZ GUANFACINE XR | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 27344 | 2022-01-06 | Abbreviated New Drug Submission (ANDS) |